Member Info for Timster

the bar is not set too high then! we *should* smash that.

Nearly sold out this week and put everything into SYME as my mate tells me its a 20 bagger :) but I couldnt bring myself to do it after waiting this long.

The tests are coming as are the cancer treatments I am 100% sure of that its just when.....

January now I reckon

is it him?

lol xxxxyyyyyyyyyyyzzzzzzzzzzz thats wee Dylan not Al

P.S - Is it us?

don't want to jinx it but the Twat team seem to have moved on...

surely you mean twats?

Is it us?

Is it us?

Is it us?

Is it us?

Are BBI a credible manufacturing partner?
BBI Solutions has served the global diagnostics industry for over 50 years, as a leading developer and manufacturer of raw materials and finished test platforms for the in-vitro diagnostics market.

Over the past 50 years, BBI has grown from a small specialist company, to a global business with manufacturing sites in five different countries, spanning three continents.

Our product ranges include:

Biological Raw Materials

Antigens
Enzymes
Monoclonal Antibodies and
Recombinant Fab Antibodies
Serum & Plasma Products

Depleted Serum
Disease State Plasma
Normal Serum and
Patient Samples
In addition, we manufacture world renowned labels for lateral flow, ELISA assay and biosensors, these include:

Gold Nanoparticles
Horseradish Peroxidase and
Glucose Oxidase

If you think no, then FFS sell up call the fca to complain about the CEO and stop moaning.

If you think yes. Then ask yourself why they are taking thier time to get this 100% nailed on to the specs that the government have specified?

Now ask yourself do BBI have a global reach?

Now ask yourself when an RNS is required? Would it be required if we had failed? Have we had an RNS yet for a failed product?

Now ask yourself is BAMS being validated? Are the timeframes defined by avacta?

.

How about everyone tries thier hardest not to respond to the c0ck wombles, no responses they will move on!

Or just create a new thread...

This is why I made the point earlier we are waiting on third parties. Validation and BBI finalising the product.

In addition to the excellent progress made with the lateral flow antigen test we are also currently carrying out a clinical evaluation of the BAMSTM assay at several sites in the UK. We are in discussions with commercial partners to establish the route to market for a CE marked BAMS COVID-19 test that can be deployed in hospitals in the UK and Europe and we continue to make good progress towards establishing a commercial partner for the research ELISA. The diagnostic business unit has also made good progress on a number of other non-COVID-19 commercial opportunities and on putting in place an ISO13485 accredited quality system to support the future growth.

Until we receive an RNS to the contrary this is whats happening!

All the absolute ****** posted on here this week is exactly that ******

Spot on daddypig, the market was never just the UK, its the whole world. Hence them talking to manufacturing partners in Asia.

Getting the test right is crucial which although frustrating is why we are waiting.

@Wyndrum what you have missed from the RNS is that there are also many mentions of BBI

it also says:
The performance of the test with clinical samples will now be evaluated as a precursor to a much larger clinical study with COVID-19 patients of known viral load to determine the clinical sensitivity of the test. In parallel BBI Solutions is working to finalise and validate the manufacturing process so that the Group can carry out a full clinical validation on the final product to support the regulatory approval process.

I presume the initial validation will be in house, and may have happened. the larger clinical study will be the next LFD related RNS

@wyndrum

Are Avacta validating there own products? No

AS has said in interviews its frustrating how long CONDOR have taken to make any progress

they are using LSTM now as well which you would think they would be contracted to deliver results in a certain time frame, but who knows!

All the news we are waiting for bar the cancer patient trial submission is out of Avacta's hands.
Other than chase there is nothing the CEO can do to speed up validation of our tests